POLARAMINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POLARAMINE (POLARAMINE).
Competitive antagonist of histamine H1 receptors, blocking the effects of histamine in the respiratory tract, vasculature, and gastrointestinal tract.
| Metabolism | Hepatic metabolism via CYP450 enzymes; primary metabolite is deschloropheniramine. |
| Excretion | Primarily renal (40-60% as unchanged drug and metabolites), with minor biliary/fecal elimination |
| Half-life | Terminal elimination half-life: 20-25 hours (range 14-36 hours). Clinical context: Supports once-daily dosing for chronic allergic symptoms; accumulation possible with hepatic impairment. |
| Protein binding | Approximately 85-90% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 3-5 L/kg (wide distribution into tissues including CNS, consistent with anticholinergic and sedative effects). |
| Bioavailability | Oral: 70-80% (first-pass metabolism reduces absolute bioavailability; syrup may have slightly faster absorption). |
| Onset of Action | Oral: 30-60 minutes (tablet or syrup). Intravenous: 5-10 minutes. Topical ophthalmic: 15-30 minutes. |
| Duration of Action | Oral: 4-6 hours for antihistamine effect, but after multiple doses, up to 24 hours due to active metabolites. Clinical note: Sedative effect may persist longer. |
| Molecular Weight | 390.87 |
| Action Class | H1 Antihistaminics (First Generation) |
| Brand Substitutes | Synramine 2mg Tablet, Geodex 2mg Tablet, Dexamine 2mg Tablet, Alermine 2mg Tablet, Dexil 2mg Tablet, Diominic 6mg Tablet, Dexaller 6mg Tablet, Dexomak 6mg Tablet |
4-8 mg orally every 6-8 hours; maximum 24 mg/day.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use caution in severe renal impairment (CrCl <10 mL/min). |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh Class C). |
| Pediatric use | Children 2-6 years: 0.1 mg/kg orally every 6 hours; maximum 2 mg/dose. Children 6-12 years: 2 mg orally every 6 hours; maximum 6 mg/day. |
| Geriatric use | Initiate at 2 mg orally every 8 hours; titrate cautiously due to increased risk of dizziness, sedation, and anticholinergic effects. |
| 1st trimester | Avoid use in first trimester unless clearly needed; risk of fetal malformations not definitively established. |
| 2nd trimester | Use only if potential benefit justifies risk; limited data on second trimester safety. |
| 3rd trimester | Avoid in third trimester due to risk of severe adverse reactions in neonates (e.g., paradoxical CNS stimulation, respiratory depression). |
Clinical note
Comprehensive clinical and safety monograph for POLARAMINE (POLARAMINE).
| Placental transfer | Crosses placenta; extent not well quantified but likely due to low molecular weight and lipophilicity. |
| Breastfeeding | Excreted into breast milk; may cause irritability, drowsiness, or paradoxical excitation in nursing infants. Use only if essential and monitor infant for adverse effects. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to dexchlorpheniramine or any componentNewborn or premature infantsBreastfeeding in large doses
| Precautions | Use with caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, bladder neck obstruction, or COPD., May cause drowsiness; avoid driving or operating machinery., Use in elderly may cause dizziness, sedation, and hypotension., Use in children may cause paradoxical hyperexcitability. |
| Food/Dietary | Avoid alcohol; may enhance CNS depression. No significant food interactions reported. Grapefruit juice may slightly increase absorption but not clinically relevant. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | Polaramine (dexchlorpheniramine) is an antihistamine; animal studies insufficient, human data limited. First trimester: potential minor malformations (cleft palate) from antihistamines overall but not established. Second/third trimester: no known fetal toxicity, but avoid near term due to possible association with retinopathy of prematurity and withdrawal symptoms (irritability, tremors) in neonates after third-trimester use. |
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. In third trimester, observe neonate for signs of anticholinergic effects (tachycardia, constipation, urinary retention) and transient withdrawal symptoms. |
| Fertility Effects | No well-documented effects on human fertility. Animal studies: no adverse effects on reproduction at clinically relevant doses. |
| Clinical Pearls |
| Polaramine (dexchlorpheniramine) is a first-generation antihistamine with potent H1-receptor antagonism. Its sedative properties can be exploited for nighttime allergy relief but caution is needed in elderly due to anticholinergic effects (confusion, urinary retention). Avoid in narrow-angle glaucoma, prostatic hyperplasia, and during pregnancy (especially first trimester). Onset of action is 15-30 minutes; duration 4-6 hours. |
| Patient Advice | This medication may cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you. · Do not consume alcohol or other central nervous system depressants while taking this drug. · Take exactly as prescribed; do not exceed the recommended dose. · If you miss a dose, skip it; do not double the next dose. · Inform your doctor if you have glaucoma, difficulty urinating, or an enlarged prostate. · Stop use and seek medical attention if you experience rapid heartbeat, hallucinations, or severe dizziness. |